Clavis Pharma is using its lipid vector technology (LVT) to develop a strong pipeline of new and improved anti-cancer drugs.
Clavis Pharma has chosen to focus on oncology (cancer treatment), due to the large unmet medical need, multiple opportunities offered by combination therapies, relatively shorter time to market ("fast track" regulatory pathways), and potentially lower cost of development.
The pharmaceutical oncology market represents the fourth largest and the fastest growing pharmaceutical market in the world, doubling in size over a six-year period to more than 70 billion USD in 2010 (Datamonitor 2011). This growth is about twice that of the overall pharmaceutical market.
Clavis Pharma has the following products in development:
- CP-4200 for the treatment of MDS (myelo dysplastic syndrome) and
- CP-4033 for the treatment of aggressive thyroid cancer (being developed by Clavis Pharma’s partner Translational Therapeutics Inc).